Loading...
Market
Will Autolus announce AUCATZYL® (obe-cel) expansion to other cancers by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Autolus Therapeutics
Story
Autolus Therapeutics Gains FDA Approval for AUCATZYL® (obe-cel) CAR-T Therapy in Leukemia
Nov 11, 2024, 12:14 PM
Autolus Therapeutics has received FDA approval for its CAR-T therapy, AUCATZYL® (obecabtagene autoleucel – obe-cel), for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This marks the first product approval for the UK-based biotech company. Autolus stock rose 9.9% pre-market following the announcement.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1-2 • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Colorectal Cancer • 25%
No Expansion • 25%
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
